Calzas Rodríguez Julia, Carmen Juarez Morales María Del, Casero Miguel Angel Racionero
Department of Medical Oncology, University Hospital Fuenlabrada, Spain.
Department of Pulmonology, University Hospital Fuenlabrada, Spain.
Respir Med Case Rep. 2016 Apr 19;18:48-50. doi: 10.1016/j.rmcr.2016.04.004. eCollection 2016.
With cisplatin-based chemotherapy, most patients with ovarian dysgerminoma will survive long-term. Bleomycin is an important part of ovarian germ cell tumors (OGCT) treatment, and its dose-limiting toxicity is the development of pulmonary toxicity and it is increased in patients older than 40 years. We report the case of an elderly patient with an unresectable ovarian dysgerminoma who received neoadjuvant chemotherapy and who developed fatal bleomycin pulmonary toxicity (BPT) after surgery. A monitoring of pulmonary function is not routinely recommended for detecting BPT, although together with carefully assessment for symptoms or signs suggestive of pulmonary toxicity is the best way to reduce the risk of BPT. The frequency of pulmonary events in older patients makes us to think about the possibility of either reduce the dose of bleomycin or removing it from the BEP in ovarian GCT.
采用基于顺铂的化疗方案，大多数卵巢无性细胞瘤患者能够长期存活。博来霉素是卵巢生殖细胞肿瘤（OGCT）治疗的重要组成部分，其剂量限制性毒性是发生肺毒性，且在40岁以上患者中这种毒性会增加。我们报告了1例老年卵巢无性细胞瘤患者，该患者接受了新辅助化疗，术后发生了致命的博来霉素肺毒性（BPT）。虽然常规不建议通过监测肺功能来检测BPT，但结合仔细评估提示肺毒性的症状或体征是降低BPT风险的最佳方法。老年患者肺部事件的发生率让我们思考是否有可能降低博来霉素的剂量或在卵巢GCT的BEP方案中去除该药。
